{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:04:16Z","timestamp":1792206256534,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR053483"],"award-info":[{"award-number":["P30AR053483"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor IgG fusion protein (<jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content>\u03b2R\u2010Ig), for the treatment of primary Sj\u00f6gren's syndrome (<jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>), and to explore the possible mechanisms of action of this treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter trial, 52 patients with primary <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content> were randomized in a 2:1 ratio to receive subcutaneous injections of 100 mg of baminercept every week for 24 weeks or matching placebo. The primary end point was the change between screening and week 24 in the stimulated whole salivary flow (<jats:styled-content style=\"fixed-case\">SWSF<\/jats:styled-content>) rate. Secondary end points included the European League Against Rheumatism Sj\u00f6gren's Syndrome Disease Activity Index (<jats:styled-content style=\"fixed-case\">ESSDAI<\/jats:styled-content>), as well as measurements of select chemokines and cytokines and enumeration of peripheral blood B and T cell subsets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The change from baseline to week 24 in the <jats:styled-content style=\"fixed-case\">SWSF<\/jats:styled-content> rate was not significantly different between the baminercept and placebo treatment groups (baseline\u2010adjusted mean change \u22120.01 versus 0.07 ml\/minute; <jats:italic>P<\/jats:italic> = 0.332). The change in the <jats:styled-content style=\"fixed-case\">ESSDAI<\/jats:styled-content> during treatment was also not significantly different between the treatment groups (baseline\u2010adjusted mean change \u22121.23 versus \u22120.15; <jats:italic>P<\/jats:italic> = 0.104). Although the incidence of adverse events was similar between the treatment groups, baminercept therapy was associated with a higher incidence of liver toxicity, including 2 serious adverse events. Baminercept also produced a significant decrease in plasma levels of <jats:styled-content style=\"fixed-case\">CXCL<\/jats:styled-content>13 and significant changes in the number of circulating B and T cells, consistent with its known inhibitory effects on <jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content>\u03b2R signaling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this trial, treatment with baminercept failed to significantly improve glandular and extraglandular disease in patients with primary <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>, despite evidence from mechanistic studies showing that it blocks <jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content>\u03b2R signaling.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40513","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T08:37:27Z","timestamp":1522485447000},"page":"1470-1480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Clinical Efficacy and Safety of Baminercept, a Lymphotoxin \u03b2 Receptor Fusion Protein, in Primary Sj\u00f6gren's Syndrome"],"prefix":"10.1002","volume":"70","author":[{"given":"E. William","family":"St.Clair","sequence":"first","affiliation":[{"name":"Duke University School of Medicine Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan N.","family":"Baer","sequence":"additional","affiliation":[{"name":"Johns Hopkins University Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungwen","family":"Wei","sequence":"additional","affiliation":[{"name":"Ignacio Sanz Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Noaiseh","sequence":"additional","affiliation":[{"name":"UPMC Presbyterian Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parke","sequence":"additional","affiliation":[{"name":"Saint Francis Medical Group Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Coca","sequence":"additional","affiliation":[{"name":"University of Rochester Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy O.","family":"Utset","sequence":"additional","affiliation":[{"name":"University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Stanford University Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McNamara","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases NIH Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Boyle","sequence":"additional","affiliation":[{"name":"Rho, Inc. Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Keyes\u2010Elstein","sequence":"additional","affiliation":[{"name":"Rho, Inc. Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Browning","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Biogen, Inc. Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Smith","sequence":"additional","affiliation":[{"name":"Emory Healthcare Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Guthridge","sequence":"additional","affiliation":[{"name":"Oklahoma Medical Research Foundation Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Sanz","sequence":"additional","affiliation":[{"name":"Ignacio Sanz Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[{"name":"Oklahoma Medical Research Foundation Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Autoimmunity Centers of Excellence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13192"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.03.004"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104728"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.7.3610"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20276"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21478"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2792"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3700"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00047"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2011.11.007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00633.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3507"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112545"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3554"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.554"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37850"},{"key":"e_1_2_9_20_1","first-page":"221","article-title":"Report of the National Eye Institute\/Industry Workshop on Clinical Trials in Dry Eyes","volume":"4","author":"Lemp MA","year":"1995","journal-title":"CLAO"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38573"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.09.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.6.670"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128269"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37828"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38734"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095954"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.03.001"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21062"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.5130"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3054"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.10.002"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2617"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600407"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/44385"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:51:01Z","timestamp":1759924261000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40513"}},"subtitle":["Results From a Phase <scp>II<\/scp> Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/art.40513"],"URL":"https:\/\/doi.org\/10.1002\/art.40513","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"2017-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}